Lexeo Therapeutics - נכסים נקיים למניה בודדת LXEO
Market valuation dynamics on GURU.Markets reflect Lexeo Therapeutics (LXEO), which specializes in precision treatment of heart and CNS pathologies, including Alzheimer's disease therapy, where the indicator stands at 3.01. A team of top-tier geneticists is retained through a stock option system, ensuring a stable workforce for conducting trials. The company's revenues are based on licensing fees and future sales of innovative drugs.
%20-%20%D7%A9%D7%95%D7%95%D7%99%20%D7%A0%D7%9B%D7%A1%D7%99%20%D7%A0%D7%A7%D7%99%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94&width=1200&height=400&colorIndex=0&v=mvq8bmkb.8d-7aozthc&start=20220704&end=20261027&filename=GURU_Markets_-_LXEO_-_Lexeo-Therapeutics_-_Net-Asset-Value-per-Share "LXEO lexeotx.com: ערך בספרים למניה בטווח 21.02.2024 - 27.10.2026 | 👁️GURU.Markets👁️")
Lexeo Therapeutics Inc. - פילוחים אנליטיים ומדדי מפתח (LXEO)
Book value per share reflects the portion of the company's net assets attributable to a single security after deducting all liabilities from total equity. By analyzing the equity per share, an investor can see the tangible asset base of Lexeo Therapeutics (LXEO), which is supported by cost optimization through the outsourcing of drug production, confirming the asset's fundamental stability.